• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Letter to the Editor Regarding "Indirect Treatment Comparisons in Healthcare Decision Making: A Targeted Review of Regulatory Approval, Reimbursement, and Pricing Recommendations Globally for Oncology Drugs in 2021-2023".

作者信息

Tomeczkowski Jörg, Leverkus Friedhelm, Bussilliat Paul, Osowski Ulrike, Herrmann Kirsten H, Eichinger Birte, Heidbrede Tanja, Schmitter Sarah, Dietrich Eva Susanne, Dintsios Charalabos-Markos, Bluhmki Tobias

机构信息

Institute for Evidence-Based Positioning in the Healthcare Sector, Bonn, Germany.

Evidence-Generating Data Evaluation, Berlin, Germany.

出版信息

Adv Ther. 2025 Aug;42(8):4096-4101. doi: 10.1007/s12325-025-03269-6. Epub 2025 Jun 20.

DOI:10.1007/s12325-025-03269-6
PMID:40540227
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12313802/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c006/12313802/50976dcf45f5/12325_2025_3269_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c006/12313802/50976dcf45f5/12325_2025_3269_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c006/12313802/50976dcf45f5/12325_2025_3269_Fig1_HTML.jpg

相似文献

1
Letter to the Editor Regarding "Indirect Treatment Comparisons in Healthcare Decision Making: A Targeted Review of Regulatory Approval, Reimbursement, and Pricing Recommendations Globally for Oncology Drugs in 2021-2023".致编辑的信：关于“医疗保健决策中的间接治疗比较：2021 - 2023年全球肿瘤药物监管批准、报销及定价建议的针对性综述”
Adv Ther. 2025 Aug;42(8):4096-4101. doi: 10.1007/s12325-025-03269-6. Epub 2025 Jun 20.
2
Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.药品政策：参考定价、其他定价及采购政策的影响
Cochrane Database Syst Rev. 2014 Oct 16;2014(10):CD005979. doi: 10.1002/14651858.CD005979.pub2.
3
Digital Therapeutics in China: Comprehensive Review.中国的数字疗法：全面综述
J Med Internet Res. 2025 May 27;27:e70955. doi: 10.2196/70955.
4
Correction to: Indirect Treatment Comparisons in Healthcare Decision Making: A Targeted Review of Regulatory Approval, Reimbursement, and Pricing Recommendations Globally for Oncology Drugs in 2021-2023.对《医疗保健决策中的间接治疗比较：2021 - 2023年全球肿瘤药物监管批准、报销和定价建议的针对性综述》的勘误
Adv Ther. 2025 Jan;42(1):70-71. doi: 10.1007/s12325-024-03087-2.
5
Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.药品政策：参考定价、其他定价及采购政策的影响
Cochrane Database Syst Rev. 2006 Apr 19(2):CD005979. doi: 10.1002/14651858.CD005979.
6
A Review and Comparative Case Study Analysis of Real-World Evidence in European Regulatory and Health Technology Assessment Decision Making for Oncology Medicines.欧洲肿瘤药物监管与卫生技术评估决策中真实世界证据的综述与比较案例研究分析
Value Health. 2025 Jan;28(1):31-41. doi: 10.1016/j.jval.2024.09.007. Epub 2024 Oct 10.
7
A Framework for Using Cost-effectiveness Analysis to Support Pricing and Reimbursement Decisions for New Pharmaceuticals in a Context of Evolving Treatments, Prices, and Evidence.在治疗方法、价格和证据不断演变的背景下，利用成本效益分析支持新药品定价和报销决策的框架。
Pharmacoeconomics. 2025 Apr;43(4):363-373. doi: 10.1007/s40273-024-01450-3. Epub 2024 Dec 31.
8
Reimbursement policies of Swiss health insurances for the surgical treatment of symptomatic breast hypertrophy: a retrospective cohort study.瑞士医疗保险对有症状性乳腺肥大手术治疗的报销政策：一项回顾性队列研究
Swiss Med Wkly. 2025 Jan 24;155:3923. doi: 10.57187/s.3923.
9
Factors that influence caregivers' and adolescents' views and practices regarding human papillomavirus (HPV) vaccination for adolescents: a qualitative evidence synthesis.影响照顾者和青少年对青少年人乳头瘤病毒（HPV）疫苗接种的看法及做法的因素：一项定性证据综合分析
Cochrane Database Syst Rev. 2025 Apr 15;4(4):CD013430. doi: 10.1002/14651858.CD013430.pub2.
10
Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis.仑伐替尼联合帕博利珠单抗治疗未经治疗的晚期肾细胞癌：系统评价和成本效果分析。
Health Technol Assess. 2024 Aug;28(49):1-190. doi: 10.3310/TRRM4238.

本文引用的文献

1
Indirect Treatment Comparisons in Healthcare Decision Making: A Targeted Review of Regulatory Approval, Reimbursement, and Pricing Recommendations Globally for Oncology Drugs in 2021-2023.医疗决策中的间接治疗比较：2021 - 2023年全球肿瘤药物监管批准、报销和定价建议的针对性综述
Adv Ther. 2025 Jan;42(1):52-69. doi: 10.1007/s12325-024-03013-6. Epub 2024 Nov 12.
2
A Framework for the Use and Likelihood of Regulatory Acceptance of Single-Arm Trials.用于监管机构接受单臂试验的可能性和使用的框架。
Ther Innov Regul Sci. 2024 Nov;58(6):1214-1232. doi: 10.1007/s43441-024-00693-8. Epub 2024 Sep 16.